|drug2807||Rapid Onsite COVID-19 Detection Wiki||1.00|
|D006402||Hematologic Diseases NIH||0.71|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is an observational prospective cohort study to evaluate the clinical course and outcomes of COVID-19 and the underlying disease in patients with hematologic disease (malignant or non-malignant).
Description: Rate of death from any causeMeasure: 30-day all-cause mortality Time: 30 day
Description: Rate of COVID-19 complicationsMeasure: COVID-19 complications Time: 30 day
Description: Rate of ICU admissionMeasure: ICU admission Time: 30 day
Description: Rate of mechanical ventilation / O2 requirementMeasure: Mechanical ventilation / O2 requirement Time: 30 day
Description: Rate of relapse or progression of hematologic diseaseMeasure: Relapse or progression of hematologic disease Time: 30 day, 90 day and 180 day
Description: Number of patients aliveMeasure: Overall survival Time: 30 day, 90 day and 180 day
Description: Putative risk factors for the severity and lethality of COVID-19Measure: Risk factors Time: 30 day, 90 day and 180 day
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports